ImmunityBio (IBRX) News Today $2.83 -0.23 (-7.52%) (As of 12/17/2024 06:00 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period ImmunityBio (NASDAQ:IBRX) Stock Price Down 5.6% - Here's WhyImmunityBio (NASDAQ:IBRX) Trading Down 5.6% - Here's WhyDecember 17 at 3:10 PM | marketbeat.comImmunityBio: Forging A New Plan After Recent $100 Million OfferingDecember 16 at 1:05 AM | seekingalpha.comImmunityBio: Despite Share Price & Funding Woes, Muddy Path To Long-Term SuccessDecember 13, 2024 | seekingalpha.comImmunityBio (NASDAQ:IBRX) Hits New 12-Month Low - Should You Sell?ImmunityBio (NASDAQ:IBRX) Sets New 52-Week Low - What's Next?December 13, 2024 | marketbeat.comD. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public OfferingDecember 12, 2024 | investing.comD. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public OfferingDecember 12, 2024 | globenewswire.comImmunityBio's Cash Burn And Dilution Dampen Anktiva's PotentialDecember 11, 2024 | seekingalpha.comImmunityBio Shares Slide 33% After Public Offering PricesDecember 11, 2024 | marketwatch.comUS Consumer Prices Rise in Line With Expectations in November as US Equity Futures Rise Pre-BellDecember 11, 2024 | msn.comImmunityBio Shares Down on Plans for Public OfferingDecember 11, 2024 | marketwatch.comImmunityBio announces common stock offering, no amount givenDecember 11, 2024 | markets.businessinsider.comImmunityBio Prices 33.33 Mln Public Offering At $3.00 Per Share, Stock DownDecember 11, 2024 | markets.businessinsider.comImmunityBio, Inc. Announces Pricing of Public Offering of Common StockDecember 11, 2024 | businesswire.comImmunityBio, Inc. Announces Proposed Public Offering of Common StockDecember 10, 2024 | businesswire.comBiotech Billionaire Soon-Shiong Sued Over ImmunityBio Stock MoveDecember 4, 2024 | msn.comImmunityBio (NASDAQ:IBRX) Receives "Buy" Rating from D. Boral CapitalD. Boral Capital reissued a "buy" rating and issued a $30.00 price objective on shares of ImmunityBio in a report on Thursday.November 25, 2024 | marketbeat.comImmunityBio partners with nCartes to streamline trialsNovember 23, 2024 | uk.investing.comImmunitybio Inc. (IBRX): Among the Most Promising Cancer Stocks According to Hedge FundsNovember 23, 2024 | msn.comImmunityBio, nCartes announce collaboration on clinical trial data fulfillmentNovember 21, 2024 | markets.businessinsider.comImmunityBio and nCartes Enter Collaboration Agreement on Clinical Trial Data FulfillmentNovember 21, 2024 | prnewswire.comImmunityBio announces new data from QUILT 3.032 studyNovember 20, 2024 | markets.businessinsider.comImmunityBio, Inc. Investor Alert (NASDAQ: IBRX): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False StatementsNovember 19, 2024 | prnewswire.comImmunityBio Reports Third-Quarter 2024 Financial ResultsNovember 12, 2024 | finance.yahoo.comImmunityBio (NASDAQ:IBRX) Stock Price Down 5.3% - Time to Sell?ImmunityBio (NASDAQ:IBRX) Shares Down 5.3% - Here's What HappenedNovember 4, 2024 | marketbeat.comPenny Stock Trades: Joby Aviation and ImmunityBioOctober 31, 2024 | baystreet.caIMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmOctober 30, 2024 | globenewswire.comImmunityBio (NASDAQ:IBRX) Stock Price Down 9.6% - Here's WhyImmunityBio (NASDAQ:IBRX) Stock Price Down 9.6% - Time to Sell?October 29, 2024 | marketbeat.comImmunityBio: CAR-NK Cell Therapy Data For NHL Expected In Second Half Of 2025October 28, 2024 | seekingalpha.comImmunityBio: 1st patient dosed in CAR-NK cell therapy study relapsed NHLOctober 25, 2024 | markets.businessinsider.comImmunityBio Inc. IBRX (U.S.: Nasdaq)October 25, 2024 | wsj.comImmunityBio Soars 56% in a Day: Is This Cancer Breakthrough the Next $30 Stock?October 25, 2024 | finance.yahoo.comImmunityBio extends gains after trial updateOctober 25, 2024 | msn.comImmunityBio: Continued Volatility Suggests Further Upside Potential, But I'd Be CarefulOctober 25, 2024 | seekingalpha.comImmunityBio (NASDAQ:IBRX) Sees Unusually-High Trading Volume - Time to Buy?ImmunityBio (NASDAQ:IBRX) Sees Large Volume Increase - Here's What HappenedOctober 25, 2024 | marketbeat.comTraders Buy Large Volume of ImmunityBio Call Options (NASDAQ:IBRX)ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) saw some unusual options trading activity on Friday. Traders purchased 9,749 call options on the company. This represents an increase of 125% compared to the typical volume of 4,330 call options.October 25, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Trading 7.8% Higher - Here's WhyImmunityBio (NASDAQ:IBRX) Shares Up 7.8% - Time to Buy?October 24, 2024 | marketbeat.comFirst Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin LymphomaOctober 24, 2024 | finance.yahoo.comImmunityBio (NASDAQ:IBRX) Upgraded to Strong-Buy by EF Hutton Acquisition Co. IEF Hutton Acquisition Co. I raised ImmunityBio to a "strong-buy" rating in a research report on Wednesday.October 24, 2024 | marketbeat.comEF Hutton Initiates Coverage of ImmunityBio (IBRX) with Buy RecommendationOctober 24, 2024 | msn.comImmunityBio initiated with a Buy at EF HuttonOctober 23, 2024 | markets.businessinsider.com800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBioOctober 23, 2024 | finance.yahoo.comImmunityBio (NASDAQ:IBRX) Shares Gap Up - Should You Buy?ImmunityBio (NASDAQ:IBRX) Shares Gap Up - Still a Buy?October 23, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Trading Up 6.2% - Time to Buy?ImmunityBio (NASDAQ:IBRX) Stock Price Up 6.2% - Here's WhyOctober 11, 2024 | marketbeat.comImmunityBio (NASDAQ:IBRX) Trading Down 4.5% - Time to Sell?ImmunityBio (NASDAQ:IBRX) Stock Price Down 4.5% - Here's WhyOctober 9, 2024 | marketbeat.comImmunityBio: Moving The NeedleOctober 7, 2024 | seekingalpha.comMore layoffs for ImmunityBio's Dunkirk facilityOctober 2, 2024 | bizjournals.comBluebird Bio To Reduce Approx. 25% Of Its Workforce - Quick FactsSeptember 24, 2024 | markets.businessinsider.comImmunityBio (NASDAQ:IBRX) Trading Down 3.2%ImmunityBio (NASDAQ:IBRX) Stock Price Down 3.2%September 17, 2024 | marketbeat.comBank of New York Mellon Corp Has $3.93 Million Holdings in ImmunityBio, Inc. (NASDAQ:IBRX)Bank of New York Mellon Corp boosted its position in shares of ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 37.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 621,536 shares of the company's stockSeptember 15, 2024 | marketbeat.comImmunitybio Inc. (IBRX): Fast-Growing Penny Stock To ConsiderSeptember 12, 2024 | msn.com Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address A conspiracy Trump won’t unseal (Ad)New documentary reveals the lost wealth-building secret hidden deep within ancient religious texts from almost every civilization… an investment one expert says is “so perfect that only God could have created it.” Watch it now to discover how this asset that you’ve likely never considered before can produce returns so safe, secure, and endless it is nothing short of miraculous. This is the untold, true story of God’s Investment. IBRX Media Mentions By Week IBRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IBRX News Sentiment▼0.520.78▲Average Medical News Sentiment IBRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IBRX Articles This Week▼143▲IBRX Articles Average Week Get ImmunityBio News Delivered to You Automatically Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ASND News RVMD News LNTH News LEGN News NUVL News BPMC News ELAN News CYTK News VKTX News TGTX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IBRX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunityBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunityBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IBRX Stock Alerts